vs

Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $109.4M, roughly 1.8× TRICO BANCSHARES ). TRICO BANCSHARES runs the higher net margin — 251.6% vs 12.0%, a 239.6% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 9.0%). TRICO BANCSHARES produced more free cash flow last quarter ($127.9M vs $38.4M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 5.4%).

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.

CORT vs TCBK — Head-to-Head

Bigger by revenue
CORT
CORT
1.8× larger
CORT
$202.1M
$109.4M
TCBK
Growing faster (revenue YoY)
CORT
CORT
+2.1% gap
CORT
11.1%
9.0%
TCBK
Higher net margin
TCBK
TCBK
239.6% more per $
TCBK
251.6%
12.0%
CORT
More free cash flow
TCBK
TCBK
$89.5M more FCF
TCBK
$127.9M
$38.4M
CORT
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
5.4%
TCBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CORT
CORT
TCBK
TCBK
Revenue
$202.1M
$109.4M
Net Profit
$24.3M
$33.6M
Gross Margin
98.7%
Operating Margin
2.2%
42.6%
Net Margin
12.0%
251.6%
Revenue YoY
11.1%
9.0%
Net Profit YoY
-21.0%
15.8%
EPS (diluted)
$0.20
$1.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CORT
CORT
TCBK
TCBK
Q4 25
$202.1M
$109.4M
Q3 25
$207.6M
$107.6M
Q2 25
$194.4M
$103.6M
Q1 25
$157.2M
$98.6M
Q4 24
$181.9M
$100.4M
Q3 24
$182.5M
$99.1M
Q2 24
$163.8M
$97.9M
Q1 24
$146.8M
$98.5M
Net Profit
CORT
CORT
TCBK
TCBK
Q4 25
$24.3M
$33.6M
Q3 25
$19.7M
$34.0M
Q2 25
$35.1M
$27.5M
Q1 25
$20.5M
$26.4M
Q4 24
$30.7M
$29.0M
Q3 24
$47.2M
$29.1M
Q2 24
$35.5M
$29.0M
Q1 24
$27.8M
$27.7M
Gross Margin
CORT
CORT
TCBK
TCBK
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Q1 24
98.3%
Operating Margin
CORT
CORT
TCBK
TCBK
Q4 25
2.2%
42.6%
Q3 25
4.9%
43.2%
Q2 25
13.7%
36.5%
Q1 25
2.2%
35.8%
Q4 24
13.9%
38.7%
Q3 24
25.5%
39.8%
Q2 24
21.7%
40.0%
Q1 24
20.1%
38.3%
Net Margin
CORT
CORT
TCBK
TCBK
Q4 25
12.0%
251.6%
Q3 25
9.5%
31.6%
Q2 25
18.1%
26.6%
Q1 25
13.1%
26.7%
Q4 24
16.9%
221.4%
Q3 24
25.9%
29.3%
Q2 24
21.7%
29.7%
Q1 24
18.9%
28.2%
EPS (diluted)
CORT
CORT
TCBK
TCBK
Q4 25
$0.20
$1.02
Q3 25
$0.16
$1.04
Q2 25
$0.29
$0.84
Q1 25
$0.17
$0.80
Q4 24
$0.25
$0.88
Q3 24
$0.41
$0.88
Q2 24
$0.32
$0.87
Q1 24
$0.25
$0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CORT
CORT
TCBK
TCBK
Cash + ST InvestmentsLiquidity on hand
$372.2M
$157.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$647.8M
$1.3B
Total Assets
$836.7M
$9.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CORT
CORT
TCBK
TCBK
Q4 25
$372.2M
$157.0M
Q3 25
$421.7M
$298.8M
Q2 25
$342.2M
$314.3M
Q1 25
$322.8M
$308.3M
Q4 24
$383.3M
$145.0M
Q3 24
$380.3M
$320.1M
Q2 24
$473.2M
$206.6M
Q1 24
$410.8M
$82.8M
Stockholders' Equity
CORT
CORT
TCBK
TCBK
Q4 25
$647.8M
$1.3B
Q3 25
$631.9M
$1.3B
Q2 25
$635.8M
$1.3B
Q1 25
$683.3M
$1.3B
Q4 24
$679.6M
$1.2B
Q3 24
$638.8M
$1.2B
Q2 24
$596.2M
$1.2B
Q1 24
$547.9M
$1.2B
Total Assets
CORT
CORT
TCBK
TCBK
Q4 25
$836.7M
$9.8B
Q3 25
$823.6M
$9.9B
Q2 25
$801.7M
$9.9B
Q1 25
$846.5M
$9.8B
Q4 24
$840.6M
$9.7B
Q3 24
$784.3M
$9.8B
Q2 24
$714.6M
$9.7B
Q1 24
$655.9M
$9.8B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CORT
CORT
TCBK
TCBK
Operating Cash FlowLast quarter
$38.4M
$133.3M
Free Cash FlowOCF − Capex
$38.4M
$127.9M
FCF MarginFCF / Revenue
19.0%
116.9%
Capex IntensityCapex / Revenue
0.0%
4.9%
Cash ConversionOCF / Net Profit
1.58×
3.96×
TTM Free Cash FlowTrailing 4 quarters
$222.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CORT
CORT
TCBK
TCBK
Q4 25
$38.4M
$133.3M
Q3 25
$54.5M
$45.1M
Q2 25
$43.9M
$29.2M
Q1 25
$5.1M
$24.5M
Q4 24
$59.3M
$109.7M
Q3 24
$73.8M
$28.6M
Q2 24
$41.2M
$31.8M
Q1 24
$23.8M
$25.1M
Free Cash Flow
CORT
CORT
TCBK
TCBK
Q4 25
$38.4M
$127.9M
Q3 25
$43.2M
Q2 25
$43.9M
$28.2M
Q1 25
$5.0M
$22.8M
Q4 24
$59.2M
$105.2M
Q3 24
$72.2M
$27.3M
Q2 24
$40.8M
$30.8M
Q1 24
$24.1M
FCF Margin
CORT
CORT
TCBK
TCBK
Q4 25
19.0%
116.9%
Q3 25
40.2%
Q2 25
22.6%
27.2%
Q1 25
3.2%
23.1%
Q4 24
32.5%
104.8%
Q3 24
39.5%
27.6%
Q2 24
24.9%
31.5%
Q1 24
24.4%
Capex Intensity
CORT
CORT
TCBK
TCBK
Q4 25
0.0%
4.9%
Q3 25
0.0%
1.7%
Q2 25
0.0%
1.0%
Q1 25
0.1%
1.7%
Q4 24
0.1%
4.5%
Q3 24
0.9%
1.3%
Q2 24
0.3%
1.0%
Q1 24
0.0%
1.0%
Cash Conversion
CORT
CORT
TCBK
TCBK
Q4 25
1.58×
3.96×
Q3 25
2.77×
1.33×
Q2 25
1.25×
1.06×
Q1 25
0.25×
0.93×
Q4 24
1.93×
3.78×
Q3 24
1.56×
0.98×
Q2 24
1.16×
1.10×
Q1 24
0.86×
0.90×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons